

HIV Associated Diarrhea: 2019

Robert Harrington, M.D.
Proud Member, MWAETC Echo Family

October 24, 2019

Disclosures

Sadly, none

HIV Associated Diarrhea: 2019

- History and Epidemiology
- Etiology
 - HIV itself
 - Infectious pathogens
 - Non-infectious causes
- Diagnostic approach
- Treatment and recommendations

History and Epidemiology

- Pre-ART era
 - Even before HIV was discovered the disease was known as slim disease in Africa, in part because of unremitting diarrhea
 - 70-100% of HIV+ patients reported frequent or chronic diarrhea
- ART era
 - 28-70% of patients report chronic diarrhea
 - From prescribing data 28% of patients on ART c/o chronic diarrhea


	Pre-ART era	ART era
Infectious	53%	13%
Non-infectious	32%	70%

History and Epidemiology

Study	Study details	Key finding
Call, Am J Gastro 2014	Retrospective 1995-97 N = 1757	Infectious: 53%→13% Non infectious 32%→70%
Knox, Am J Gastro 2000	Retrospective 1996-7 N = 671	Diarrhea 39%
Zingmond JAIDS 2003	Two X sectional cohorts (1996-2000) N = 3745	Diarrhea 53%
Siddiqui J Clin Gastro 2007	Prospective study 2002-03 N = 416	Diarrhea 28% (HIV+) Vs 7% (HIV-)
DaCosta DiBonaventura AIDS Care 2012	X sectional of patients on ART 2008 N = 953	ART related diarrhea 63%

Etiology: HIV


- HIV Enteropathy
 - Can occur at any stage of HIV although more common in those with advanced, untreated HIV
 - Pathogenesis:
 - Profound depletion of gut-associated CD4 cells, especially CD4-TH-17 subset (involved in epithelial cell repair)
 - Increase in activated CD8 cells – promotes inflammation
 - Leading to gut leakage, bacterial translocation and malabsorption
 - Histologically: crypt cell proliferation → encroaches on villi → atrophy of villi
 - Clinically: malabsorption, weight loss



Note:
Blunted villi
Distorted crypts
Influx of lymphocytes

Etiology: Infectious Pathogens

- Bacteria
- Protozoa
- Fungi
- Viruses



Etiology: Bacteria

- *Campylobacter* spp.: (small bowel) a common cause of bacteremia in the pre-ART era
- *Salmonella* spp: (small bowel) common cause of bacteremia in the pre-ART, pre-TMP/SMX era. More common now in advanced, untreated HIV, especially in Africa and Russia.
- *Shigella* spp and pathogenic *E coli* (same organism?) (colon)
 - Now an STI
 - Outbreaks in Asia, Europe, North America
 - UK study: 2003-15: 20% of all non-travel related cases occurred in HIV+ (Vs 3% of travel-associated cases), 93% were men and 98% MSM. Highly associated with condomless sex
 - Often macrolide resistant – likely due to azithromycin exposure for the treatment of STIs

Etiology: Bacteria

- Gastroenteritis in MSM in Seattle (majority HIV+)
 - Cohort study of 235 MSM underwent stool pcr testing (January 2017- June 2018)
 - Testing was positive in 151/268 (episodes) = 60%

Pathogen	Percent detected
Bacteria	88.7%
<i>E coli</i>	33.1%
<i>Shigella</i>	30.5%
<i>Campylobacter</i>	17.2%
Parasite	40%
<i>Giardia</i>	20.5%
<i>Cryptosporidia</i>	6%
Virus (mostly norovirus)	26%

- Resistance:
 - *Shigella* (19 isolates) all R to ampicillin and TMP/SMX, 17/19 resistant to azithromycin, 1/19 R to cipro
 - *Campylobacter* (9 isolates): 7/9 R to cipro, 8/9 R to erythromycin

Etiology: Bacteria

- LGV: procto-colitis: (rectum) More common in Africa, SEA, India and South America > North America and Europe.
 - Sharp rise in London in 2012-15, 74% HIV+
- *Clostridioides difficile*: (colon) more common in HIV+, especially in those with advanced disease (CD4 < 50)
- *Mycobacterium avium complex*: (small bowel) in those with CD4 < 50. Chronic infection with fever, sweats, weight loss, diarrhea, malabsorption, organomegaly, anemia, hepatitis

Etiology: Protozoa

- *Giardia lamblia*: (small bowel) more severe, protracted disease in persons with HIV
- *E. histolytica*: (colon) more common in Asia-Pacific MSM. In Taiwan study 45% were HIV+
- *Cryptosporidia* spp (hominis and parvum): (small bowel) prolonged, severe and occasionally fatal disease. More common in underdeveloped countries but 60,000 cases annually in the US
- *Cystoisospora belli*: (small bowel): tropical and sub-tropical regions

Etiology: Fungi and Viruses

- Microsporidia (*Enterocytozoon bieneusi* > *Encephalitozoon intestinalis*): (small bowel) CD4 < 100
- *Histoplasma capsulatum*: (small bowel) rare cause of diarrhea in those from endemic regions with disseminated infections
- CMV: (colon > esophagus and small bowel): CD4 < 50, causes deep painful ulcerations
- HSV: (esophagus, rectum > small bowel and colon)
- Other viruses: rotovirus, astrovirus, norovirus, sapovirus

Etiology: Non-infectious

- ART associated
 - 2007(Siddiqui): PI: 38%, non-PI: 17%
 - 2013 (prescribing data) : Overall: 28%
 - PI 13.6%
 - NRTI 10%
 - NNRTI 2.2%
 - II and MRV < 1%
- Dutch study (Smit, 2013), N = 10,278

Diarrhea = reason for switching ART	Percent
1996-2000	36.2%
2001-05	24.9%
2005-2010	15.3%

Etiology: Non-infectious

- Mechanisms:

- Enhanced Ca^{++} signaling of secretory cells \rightarrow increased Cl^- in the lumen followed by Na^+ and water (Nelfinavir)
- Increased enterocyte apoptosis \rightarrow leaky epithelium (RTV and LPV - PIs)

Class/drug	Reported Incidence of diarrhea
Protease inhibitors	
Lopinavir/RTV	7-28
Atazanavir/RTV	2-3
Darunavir/RTV	9-14
Nucleoside RTI	
TDF	9-16
TAF	?
Abacavir	7
Non-nucleoside RTI	
Efavirenz	3-14
Nevirapine	< 1-2
Rilpivirine	< 2
Etravirine	0
Doravirine	3-5%
Integrase inhibitors	
Raltegravir	< 1
Dolutegravir	~ 1
Elvitegravir/C	12
Bictegravir	3-6

Diagnostic Approach

- History and exam
 - Small intestine: voluminous, watery, weight loss, bloating, cramping, post-prandial diarrhea
 - Colon/rectum: tenesmus, painful defecation, hematochezia, small, frequent bowel movements
 - Organomegaly: MAC, histoplasma, cancer
- Stool examination
 - Bacterial culture, Ova and parasite exam, NA testing (biofire)
- Endoscopy
 - CMV, HSV, MAC, KS, Histoplasma

Treatment

- Targeted therapy for infectious pathogens or cancers
- Probiotics: small studies with mixed results (also cases of lactobacillus bacteremia with excessive use!)
- Diet modification: Low fat, lactose-free, high fiber, caffeine-free) why not?
- Bovine serum IgG: PC, clinical trial, N = 103 – no difference
- L-glutamine: PC study, N = 25, some benefit
- Curcumin (turmeric), single study of 8 patients: 100% effective! And who doesn't like Indian food

Treatment


- Adsorbents/Anti-motility agents
 - Cochrane review: insufficient evidence for their use
 - Bismuth subsalicylate and attapulgite – unproven
 - Bulking agents (psyllium, oat bran) – do not work
 - Loperamide: (opioid receptor agonist)
 - Potential DI with PIs but does not cross the BBB so little worry
 - Familiar, established effect, safe, cheap
 - Lomotil (diphenoxylate/atropine)
 - Does cross the BBB – abuse potential
 - Those who fail loperamide generally are not rescued with Lomotil
 - Tincture of opium – abuse potential

Treatment

- Anti-secretory agents
 - Octreotide: somatostatin analogue
 - Alters binding of VIP
 - Decreased diarrhea by 50% in one study of 51 patients (Cello)
 - AEs: hypo and hyperglycemia, nausea, abdominal pain
 - Is administered sub-q
 - Cost: ~\$250/month

Treatment

- Anti-secretory agents
 - Crofelemer: derived from the sap of the S American tree, *Croton lechleri*
 - Inhibits Cl⁻ ion channels in intestinal epithelium through inhibition of Ca⁺⁺ and cAMP activation
 - Advent study, N = 376
 - Reduced diarrhea by 17.6% (Vs 8%)
 - Not absorbed, has no DIs and no AEs
 - Cost \$6-700/month (with a free on-line coupon!)



Sangre De Drago (Dragon's blood)



Summary

- HIV-associated diarrhea remains an issue for many patients but the prevalence has decreased from nearly 100% to 28%
- Treat identified pathogens with targeted therapy
- Treat HIV enteropathy with ART
- If ART-related: Change ART: avoid PIs, Efavirenz, Cobicistat and perhaps TDF (TAF may be better)
- Non-specific therapy: loperamide, dietary changes, good Indian food
- Last resort: Octreotide or Dragon's blood



Acknowledgment

The Mountain West AIDS Education and Training (MWAETC) program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$2,972,660 with 0% financed with non-governmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.



National HIV/AIDS Consultation Resources

- **Clinician Consultation Center** www.nccc.ucsf.edu
- **HIV/AIDS Management (Warmline)** 1-800-933-3413
M-F, 6am - 5pm PST
- **PEPline** 1-888-HIV-4911
Every day, 6am - 6pm PST
- **PrEPline** 1-855-HIV-PrEP
M-F, 8am - 3pm PST
- **Perinatal HIV Hotline** 1-888-HIV-8765
24/7